These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 25394055)

  • 41. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.
    Riddler SA; Li X; Chu H; Kingsley LA; Dobs A; Evans R; Palella F; Visscher B; Chmiel JS; Sharrett A
    HIV Med; 2007 Jul; 8(5):280-7. PubMed ID: 17561873
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inflammatory cardiovascular risk markers in women with hypopituitarism.
    Sesmilo G; Miller KK; Hayden D; Klibanski A
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5774-81. PubMed ID: 11739438
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy.
    Begovac J; Dragović G; Višković K; Kušić J; Perović Mihanović M; Lukas D; Jevtović Đ
    Croat Med J; 2015 Feb; 56(1):14-23. PubMed ID: 25727038
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Changes in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL study.
    Cahn P; Villanueva JA; Arribas J; Gatell J; Lama J; Norton M; Patterson P; Madero JS; Sued O; Figueroa MI; Rolón MJ
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19554. PubMed ID: 25394061
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enhancing Atorvastatin In Vivo Oral Bioavailability in the Presence of Inflammatory Bowel Disease and Irritable Bowel Syndrome Using Supercritical Fluid Technology Guided by wbPBPK Modeling in Rat and Human.
    Alsmadi MM; Al-Daoud NM; Obaidat RM; Abu-Farsakh NA
    AAPS PharmSciTech; 2022 May; 23(5):148. PubMed ID: 35585214
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Good Fences Make Good Neighbors: Human Immunodeficiency Virus and Vascular Disease.
    Mayne ES; Louw S
    Open Forum Infect Dis; 2019 Nov; 6(11):ofz303. PubMed ID: 31737735
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Utility of the Lipoprotein-Associated Phospholipase A
    Mayne ES; Moabi H; Grobbee DE; Barth RE; Klipstein-Grobusch K; Stevens WS; Vos AG; Louw S
    Clin Appl Thromb Hemost; 2019; 25():1076029619883944. PubMed ID: 31686546
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Platelet secretion in inflammatory and infectious diseases.
    Manne BK; Xiang SC; Rondina MT
    Platelets; 2017 Mar; 28(2):155-164. PubMed ID: 27848259
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of immune recovery with hyperlipidaemia and apolipoprotein gene polymorphisms following highly active antiretroviral therapy in a cohort of Chinese HIV patients.
    Chan DP; Lee MP; Wong NS; Leung RK; Naftalin CM; Lee SS
    BMJ Open; 2016 Apr; 6(4):e010998. PubMed ID: 27067897
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular markers of inflammation and serum lipid levels in HIV-infected patients with undetectable viraemia.
    Viskovic K; Zidovec-Lepej S; Gorenec L; Grgic I; Lukas D; Zekan S; Dragobratovic A; Begovac J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19548. PubMed ID: 25394055
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiovascular markers of inflammation and serum lipid levels in HIV-infected patients with undetectable viremia.
    Višković K; Židovec Lepej S; Gorenec A; Grgić I; Lukas D; Zekan Š; Dragobratović A; Trupković M; Begovac J
    Sci Rep; 2018 Apr; 8(1):6113. PubMed ID: 29666424
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
    Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients.
    Bastard JP; Soulié C; Fellahi S; Haïm-Boukobza S; Simon A; Katlama C; Calvez V; Marcelin AG; Capeau J
    Antivir Ther; 2012; 17(5):915-9. PubMed ID: 22436412
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.